Shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) rose 4.3% during trading on Wednesday . The stock traded as high as $0.24 and last traded at $0.24, approximately 14,910 shares were traded during trading. A decline of 99% from the average daily volume of 1,060,599 shares. The stock had previously closed at $0.23.
ATNM has been the topic of a number of research reports. Zacks Investment Research lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 4th. William Blair started coverage on shares of Actinium Pharmaceuticals in a research report on Thursday, August 8th. They set an “outperform” rating for the company. Finally, Maxim Group set a $3.00 price objective on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, June 4th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $3.56.
A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. Oppenheimer & Co. Inc. grew its stake in Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 34.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,281 shares of the biotechnology company’s stock after acquiring an additional 60,769 shares during the period. Oppenheimer & Co. Inc. owned 0.15% of Actinium Pharmaceuticals worth $58,000 at the end of the most recent quarter.
Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Further Reading: Coverage Ratio
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.